Running Head: Identification of 4 Unique Subtypes of TNBCs.
INTRODUCTION
Recent studies have demonstrated that breast cancer heterogeneity extends beyond the classic immunohistochemistry (IHC)-based divisions of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her-2)
1 . 10-20% of primary breast cancers are triple-negative breast cancers (TNBCs) 2 , which lack expression of ER, PR and Her2, present with higher grade, often contain mutations in TP53 3 , and have a poor prognosis 4 . Molecularly-targeted therapy has
shown limited benefit so far in TNBCs, and although PARP inhibitors in the BRCAmutant setting are promising 5, 6 , new strategies for classifying and treating women affected by this aggressive disease are urgently needed.
The intrinsic subtyping of breast cancer by gene expression analyses 7 was recently supported by The Cancer Genome Atlas (TCGA) Program through mRNA, miRNA, DNA, and epigenetic analyses 8 . The basal-like subtype, traditionally defined by RNA profiling or cytokeratin expression 9 , account for 10-25% of all invasive breast cancers 10 . In addition, basal-like breast cancers account for 47-88% of all TNBCs 8, 11, 12 .
Tumors of the "claudin-low" (CL) subtype 13, 14 have particularly poor prognoses compared to hormone-sensitive tumors 15 . The results from an aggregate analysis of publically available expression data sets performed by Lehmann et al. 12 suggested that
TNBCs are more heterogeneous than previously described, and identified 6 subtypes:
1) androgen receptor positive; 2) claudin-low-enriched mesenchymal; 3) mesenchymal stem-like; 4) immune response; and two cell cycle-disrupted basal subtypes 5) BL-1 and 6) BL-2. However, immunohistochemical (IHC) detection of ER, PR, and HER2 protein is the clinical standard used to define TNBC. In the study by Lehmann et al., when Research.
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Author Manuscript Published OnlineFirst on September 10, 2014; DOI: 10.1158/1078-0432.CCR- tumors with IHC-confirmed ER, PR, and HER2 protein expression were analyzed, only 5 of the 6 described subtypes were observed (see supplemental figures 4 and 5 in Lehmann et al. 12 ). Therefore, while previous genomic studies have advanced our understanding of TNBCs, stable subtypes, as well as subtype-specific molecular targets still need to be identified.
In this study, we investigated 198 previously uncharacterized TNBCs using mRNA expression and DNA profiling, and identified 4 stable TNBC subtypes: 1)
Luminal/Androgen Receptor (LAR), 2) Mesenchymal (MES), 3) Basal-Like Immune Suppressed (BLIS), and 4) Basal-Like Immune Activated (BLIA Center pathologists. Only tumors exhibiting >50% tumor cellularity were used. ERreceptor negativity is defined as Allred Scale ≤2.
RNA/DNA extraction and array experiments
For extraction and quality control details, see supplemental material. Briefly, tumors were profiled using the Affymetrix U133 Plus 2.0 gene expression array and affy 16 package in R 17 . Discovery and validation set SNP experiments were performed on Illumina 610K and 660K platforms, respectively. Common SNPs were analyzed after independent processing in Illumina Genome Studio v2011 Genotyping Module 1.9.4.
PAM50, TNBCType, and ERSig
TNBCs were assigned to previously described subtypes using the TNBCType tool 18 . Intrinsic subtypes were established with the PAM50 Breast Cancer Intrinsic Gene selection, NMF clustering, differential expression, and centroid signatures Genes were sorted by aggregate rank of median absolute deviations (MADs) across all samples and the MAD across each of the two most predominant clusters (approximating basal-like versus the remaining intrinsic subtypes) for the discovery set using R package Differential Expression via Distance Summary (DEDS) 22 . The top 1000 median-centered genes were utilized for clustering and split into 2000 positive input features 23 . The ideal rank basis and factorization algorithm was determined using the R package Non-negative Matrix Factorization (NMF) 24 before taking the 1000-iteration consensus for a final clustering basis of 4.
Genes were sorted by DEDS using: 1) Goeman's Global Test (GGT) 25 were analyzed by IPA to produce final gene lists. 
Copy number segmentation and analysis
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Survival analyses
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on April Survival curves were constructed using the Kaplan-Meier product limit method and compared between subtypes with the log-rank test using publically available datasets for which disease-free survival and disease-specific survival results are available; however, no treatment information was available for these datasets. Cox proportional hazard regression model adjusted for available prognostic clinical covariates was performed to calculate subtype-specific hazard ratios, 95% confidence intervals, and disease-free and overall survival (DFS and OS, respectively). Survival analyses were performed using the R package survival.
RESULTS
Patient population
198 TNBCs were assigned to discovery (n=84) or validation (n=114) sets based on chronological acquisition of tissue. Subjects were predominantly postmenopausal, Caucasian, and of mean and median age of 53 ( Table 1) . 95% of TNBCs were invasive ductal carcinomas, predominantly Stages I-III (1% were metastatic breast cancers), and >75% of tumors were >2cm at diagnosis.
mRNA profiling of TNBCs reveals four stable molecular phenotypes
Using RNA gene expression profiling, we explored TNBC molecular phenotypes.
NMF was performed on 1000 discovery set genes selected to maximize separation across and within conventional intrinsic subtypes. These tumors were most stably divided into 4 clusters by cophenetic, dispersion, silhouette, and Statistical Significance of Clustering (SigClust) 30 metrics, in addition to visual inspection of the consensus heat map (Figures 1A-B, S1 ). This quadrilateral division of data was also observed in the validation set tumors using the same input features (Figures 1D-E, S2 ). ER-, PR-and Her2-negativity was IHC-confirmed by our participating pathologist, Dr. Contreras 
Gene signatures define four prognostically-distinct TNBC subtypes
Using the discovery and validation sets we developed and confirmed an 80-gene signature for these clusters (Figure 2A , Tables S11-16 ). This analysis was repeated using an independent set of 221 publically accessible TNBCs with IHC data ("external Clinical outcome data was available for this publically available "external set" of TNBCs. However, treatment information for the "external set" data is not available.
Analysis of disease-free survival (DFS) and disease-specific survival (DSS) showed that subtype 3 has the worst prognosis of all 4 subtypes, while subtype 4 has a relatively good prognosis for DFS (logrank test p=0.042 and 0.041, respectively) and diseasespecific survival (DSS; logrank test p=0.039 and 0.029, respectively) (Tables S23-24, Figure 2C ). The associations between subtypes 3 and 4 and DFS and DSS remained significant in multivariate models adjusted for available prognostic clinical covariates..
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DNA copy number analysis identifies TNBC subtype-specific focal changes
We next investigated TNBC subtype-defined CN variation (CNV) by ploidy-and Our results also demonstrate subtype-specific molecular expression, thereby enabling TNBC subtype classification based on molecules they do express as opposed to molecules they do not express. Lehmann's TNBC-subtyping study identified six TNBC subtypes through the combined analysis of 14 RNA profiling datasets ("discovery dataset") 12 . Assignment to these subtypes was confirmed using a second dataset comprised of 7 other publicallyavailable datasets, however all six subtypes were not detected when subtyping was limited to only those tumors with ER, PR, and HER2 IHC data. In addition, basal-like-1 and basal-like-2 tumors are not readily distinguishable by hierarchical clustering of public TNBC data sets using Lehmann's gene signatures 32 , despite demonstration of molecular heterogeneity beyond the classic intrinsic subtypes. In Lehmann's study, TNBCs strongly segregated into stromal, immune, and basal gene modules, partially supporting our model. Additional studies have also demonstrated that an immune signature is an important clinical predictor for ER-negative tumors 33, 27, 34 . The large set of ER-, PR-, and HER2-characterized tumors used in our study enabled us to further
